Systems Medicine of Mitochondrial Parkinson’s Disease View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2015-2019

FUNDING AMOUNT

5999990 EUR

ABSTRACT

The overall objective of this project is to identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson’s disease (PD) patients with overt mitochondrial dysfunction. Multi-modal phenotypic characterisation of cohorts of monogenic PD patients with overt mitochondrial dysfunction will be used as an anchor for the discovery of two extreme cohorts of idiopathic PD patients: with and without detectable mitochondrial dysfunction. A suite of personalised in vitro, in vivo, and in silico models will be generated using induced pluripotent stem cells (iPSCs) from selected subjects and controls. An industrial quality 3D microfluidic cell culture product, specifically designed for the culture of iPSC-derived dopaminergic neurons, will be developed for use in a morphological and bioanalytical screen for lead compounds reduce mitochondrial dysfunction. By monitoring motor behaviour and in situ striatal neurochemistry at high temporal resolution, the in vivo response to lead compounds will be characterised in humanised mouse models with striatally transplants of iPSC-derived dopaminergic neurons derived from PD patients. Personalised computational models of dopaminergic neuronal metabolism and mitochondrial morphology will be developed. These in silico models will be used to accelerate drug development by prioritising pathways for metabolomic assay optimisation, stratifying idiopathic PD patients by degree of mitochondrial dysfunction, predicting new new targets to reduce mitochondrial dysfunction and mechanistic interpretation in vitro and in vivo experimental results. SysMedPD unites a highly experienced multidisciplinary consortium in an ambitious project to develop and apply a systems biomedicine approach to preclinically identify candidate neuroprotectants, for the estimated 1-2 million people worldwide who suffer from PD with mitochondrial dysfunction. More... »

URL

http://cordis.europa.eu/project/rcn/199759_en.html

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "EUR", 
      "type": "MonetaryAmount", 
      "value": "5999990"
    }, 
    "description": "The overall objective of this project is to identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson\u2019s disease (PD) patients with overt mitochondrial dysfunction. Multi-modal phenotypic characterisation of cohorts of monogenic PD patients with overt mitochondrial dysfunction will be used as an anchor for the discovery of two extreme cohorts of idiopathic PD patients: with and without detectable mitochondrial dysfunction. A suite of personalised in vitro, in vivo, and in silico models will be generated using induced pluripotent stem cells (iPSCs) from selected subjects and controls. An industrial quality 3D microfluidic cell culture product, specifically designed for the culture of iPSC-derived dopaminergic neurons, will be developed for use in a morphological and bioanalytical screen for lead compounds reduce mitochondrial dysfunction. By monitoring motor behaviour and in situ striatal neurochemistry at high temporal resolution, the in vivo response to lead compounds will be characterised in humanised mouse models with striatally transplants of iPSC-derived dopaminergic neurons derived from PD patients. Personalised computational models of dopaminergic neuronal metabolism and mitochondrial morphology will be developed. These in silico models will be used to accelerate drug development by prioritising pathways for metabolomic assay optimisation, stratifying idiopathic PD patients by degree of mitochondrial dysfunction, predicting new new targets to reduce mitochondrial dysfunction and mechanistic interpretation in vitro and in vivo experimental results. SysMedPD unites a highly experienced multidisciplinary consortium in an ambitious project to develop and apply a systems biomedicine approach to preclinically identify candidate neuroprotectants, for the estimated 1-2 million people worldwide who suffer from PD with mitochondrial dysfunction.", 
    "endDate": "2019-11-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.270680.b", 
      "type": "Organization"
    }, 
    "id": "sg:grant.5051063", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "5051063"
        ]
      }, 
      {
        "name": "cordis_id", 
        "type": "PropertyValue", 
        "value": [
          "199759"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "cohort", 
      "experimental results", 
      "lead compounds", 
      "control", 
      "neurodegeneration", 
      "multidisciplinary consortium", 
      "PD patients", 
      "industrial quality 3D microfluidic cell culture product", 
      "striatally transplants", 
      "pluripotent stem cells", 
      "vivo response", 
      "compounds", 
      "Systems Medicine", 
      "culture", 
      "candidate neuroprotectants", 
      "high temporal resolution", 
      "vitro", 
      "ambitious project", 
      "monogenic PD patients", 
      "dopaminergic neuronal metabolism", 
      "humanised mouse model", 
      "personalised computational models", 
      "idiopathic PD patients", 
      "discovery", 
      "pathway", 
      "Mitochondrial Parkinson\u2019s Disease", 
      "use", 
      "suite", 
      "mitochondrial morphology", 
      "extreme cohorts", 
      "mechanistic interpretation", 
      "Multi-modal phenotypic characterisation", 
      "metabolomic assay optimisation", 
      "detectable mitochondrial dysfunction", 
      "bioanalytical screen", 
      "overt mitochondrial dysfunction", 
      "situ", 
      "motor behavior", 
      "new new targets", 
      "silico models", 
      "SysMedPD", 
      "mitochondrial dysfunction", 
      "vivo", 
      "project", 
      "people", 
      "novel drug candidates", 
      "subset", 
      "degree", 
      "patients", 
      "Parkinson's disease", 
      "drug development", 
      "dopaminergic neurons", 
      "subjects", 
      "anchor", 
      "systems biomedicine approach", 
      "iPSC", 
      "striatal neurochemistry", 
      "overall objective", 
      "progression"
    ], 
    "name": "Systems Medicine of Mitochondrial Parkinson\u2019s Disease", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.476437.5", 
        "type": "Organization"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.5051063"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T11:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/cordis_projects_4.xml.gz", 
    "startDate": "2015-12-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://cordis.europa.eu/project/rcn/199759_en.html"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.5051063'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.5051063'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.5051063'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.5051063'


 

This table displays all metadata directly associated to this object as RDF triples.

93 TRIPLES      19 PREDICATES      79 URIs      72 LITERALS      4 BLANK NODES

Subject Predicate Object
1 sg:grant.5051063 schema:about anzsrc-for:2211
2 schema:amount N41e846e98d93413187e2b2019cadf072
3 schema:description The overall objective of this project is to identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson’s disease (PD) patients with overt mitochondrial dysfunction. Multi-modal phenotypic characterisation of cohorts of monogenic PD patients with overt mitochondrial dysfunction will be used as an anchor for the discovery of two extreme cohorts of idiopathic PD patients: with and without detectable mitochondrial dysfunction. A suite of personalised in vitro, in vivo, and in silico models will be generated using induced pluripotent stem cells (iPSCs) from selected subjects and controls. An industrial quality 3D microfluidic cell culture product, specifically designed for the culture of iPSC-derived dopaminergic neurons, will be developed for use in a morphological and bioanalytical screen for lead compounds reduce mitochondrial dysfunction. By monitoring motor behaviour and in situ striatal neurochemistry at high temporal resolution, the in vivo response to lead compounds will be characterised in humanised mouse models with striatally transplants of iPSC-derived dopaminergic neurons derived from PD patients. Personalised computational models of dopaminergic neuronal metabolism and mitochondrial morphology will be developed. These in silico models will be used to accelerate drug development by prioritising pathways for metabolomic assay optimisation, stratifying idiopathic PD patients by degree of mitochondrial dysfunction, predicting new new targets to reduce mitochondrial dysfunction and mechanistic interpretation in vitro and in vivo experimental results. SysMedPD unites a highly experienced multidisciplinary consortium in an ambitious project to develop and apply a systems biomedicine approach to preclinically identify candidate neuroprotectants, for the estimated 1-2 million people worldwide who suffer from PD with mitochondrial dysfunction.
4 schema:endDate 2019-11-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.270680.b
6 schema:identifier Nb6a1c54276c04492ae0403ea3dc9ecc4
7 Nd00bb650dc8145e79b8fe4c6d06332cc
8 schema:inLanguage en
9 schema:keywords Mitochondrial Parkinson’s Disease
10 Multi-modal phenotypic characterisation
11 PD patients
12 Parkinson's disease
13 SysMedPD
14 Systems Medicine
15 ambitious project
16 anchor
17 bioanalytical screen
18 candidate neuroprotectants
19 cohort
20 compounds
21 control
22 culture
23 degree
24 detectable mitochondrial dysfunction
25 discovery
26 dopaminergic neuronal metabolism
27 dopaminergic neurons
28 drug development
29 experimental results
30 extreme cohorts
31 high temporal resolution
32 humanised mouse model
33 iPSC
34 idiopathic PD patients
35 industrial quality 3D microfluidic cell culture product
36 lead compounds
37 mechanistic interpretation
38 metabolomic assay optimisation
39 mitochondrial dysfunction
40 mitochondrial morphology
41 monogenic PD patients
42 motor behavior
43 multidisciplinary consortium
44 neurodegeneration
45 new new targets
46 novel drug candidates
47 overall objective
48 overt mitochondrial dysfunction
49 pathway
50 patients
51 people
52 personalised computational models
53 pluripotent stem cells
54 progression
55 project
56 silico models
57 situ
58 striatal neurochemistry
59 striatally transplants
60 subjects
61 subset
62 suite
63 systems biomedicine approach
64 use
65 vitro
66 vivo
67 vivo response
68 schema:name Systems Medicine of Mitochondrial Parkinson’s Disease
69 schema:recipient https://www.grid.ac/institutes/grid.476437.5
70 schema:sameAs https://app.dimensions.ai/details/grant/grant.5051063
71 schema:sdDatePublished 2019-03-07T11:23
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N7a93d38168d646e58dde9d1a967e939a
74 schema:startDate 2015-12-01T00:00:00Z
75 schema:url http://cordis.europa.eu/project/rcn/199759_en.html
76 sgo:license sg:explorer/license/
77 sgo:sdDataset grants
78 rdf:type schema:MonetaryGrant
79 N41e846e98d93413187e2b2019cadf072 schema:currency EUR
80 schema:value 5999990
81 rdf:type schema:MonetaryAmount
82 N7a93d38168d646e58dde9d1a967e939a schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 Nb6a1c54276c04492ae0403ea3dc9ecc4 schema:name dimensions_id
85 schema:value 5051063
86 rdf:type schema:PropertyValue
87 Nd00bb650dc8145e79b8fe4c6d06332cc schema:name cordis_id
88 schema:value 199759
89 rdf:type schema:PropertyValue
90 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
91 rdf:type schema:DefinedTerm
92 https://www.grid.ac/institutes/grid.270680.b schema:Organization
93 https://www.grid.ac/institutes/grid.476437.5 schema:Organization
 




Preview window. Press ESC to close (or click here)


...